Current treatment and clinical trials in ovarian cancer

Expert Opinion on Investigational Drugs

Volumn 19, Issue 4, 2010, Pages 521-534

  Han, Liz Y ^a   Kipps, Emma ^a   Kaye, Stan B ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Anti angiogenic therapies; Ovarian cancer clinical trials; Phase II III trials; Platinum and taxanes; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; FARLETUZUMAB; GEFITINIB; GEMCITABINE; IMATINIB; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; OLAPARIB; OREGOVOMAB; PACLITAXEL; PERTUZUMAB; PLACEBO; PLATINUM COMPLEX; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CYTOTOXICITY; DISEASE SEVERITY; DNA DAMAGE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HOMOLOGOUS RECOMBINATION; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; ANIMAL; CLINICAL TRIAL (TOPIC); FEMALE; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 77952496673     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003647966     Document Type: Review

References (88)

1. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005;15(Suppl 1):3-11
2. Williams CJ, Mead GM, Macbeth FR, et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol 1985;3:1455-1462
3. Decker DG, Fleming TR, Malkasian GD, Jr., et al. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 1982;60:481-487
4. Omura GA, Bundy BN, Berek JS, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:457-465
5. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-279
6. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6
7. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708
8. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-3092
9. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-1329
10. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200
11. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000;18:106-115
12. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-515
13. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-1425
14. De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004;22:2635-2642
15. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006;24:1127-1135
16. Herrstedt J, Huober J, Priou F, et al. A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients. 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(Suppl):18s
17. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-1691
18. Pignata S, Scambia G, Savarese A, et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO-2 randomized multicenter trial. 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(Suppl):18s
19. Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996;14:2113-2119
20. Kaye SB, Vasey P, Rustin G, et al. Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: an SGCTG study (SCOTROC 4). 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(Suppl):15s
21. Mobus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007;25:4187-4193
22. Isonishi S, Yasuda M, Takahashi F, et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. 2008 ASCO Annual Meeting. J Clin Oncol 2008;26(Suppl):abstract 5506
23. Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95:125-132
24. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105-112
25. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102:432-439
26. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021-1027
27. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955
28. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-1007
29. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43
30. Kaye SB. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol 2007;25:5150-5152
31. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186
32. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-516
33. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465
34. Ozols RF. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol 2003;21:2451-2453
35. Muss HB, Case LD, Richards F II, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991;325:1342-1348
36. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987;317:1490-1495
37. Thigpen T. Maybe more is better. J Clin Oncol 2003;21:2454-6
38. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m(2)) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group Phase 3 trial. Gynecol Oncol 2009;114(2):195-198
39. Conte PF, Favalli G, Gadducci A, et al. Final results of After-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel in advanced ovarian cancer patients in complete response after platinum-paclitaxel chemotherapy. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl):18S
40. Gadducci A, Katsaros D, Zola P, et al. Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative Phase 2 multicenter Italian study (after-6 protocol 2). Int J Gynecol Cancer 2009;19:615-619
41. Skinner EN, Boruta DM, Gehrig PA, et al. Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-up. Gynecol Oncol 2005;98:59-62
42. Linch M, Stavridi F, Hook J, et al. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecol Oncol 2008;109:27-32
43. Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009;27:418-425
44. Ledermann JA, Rustin G, Hackshaw A, et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following reatment of relapsed ovarian cancer. 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(Suppl):15s
45. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134
46. Chen X, Horiuchi A, Kikuchi N, et al. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer Sci 2007;98:68-76
47. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-393
48. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990;36:207-211 (Pubitemid 20061287)
49. Buyse M, Burzykowski T, Parmar M, et al. Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. J Clin Oncol 2003;21:1682-1687
50. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-2106
51. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-4707
52. Avall-Lundqvist E, Wimberger P, Gladieff L, et al. Pegylated liposomal doxorubicin-carboplatin vs. paclitaxel-carboplatin in relapsing sensitive ovarian cancer: a 500 patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study. 2008 ASCO Annual Meeting 26. J Clin Oncol 2008;26(Suppl):abstract 5565
53. Pujade-Lauraine E, Mahner S, Kaern J, et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer: CALPYPSO study of the Gynecologic Cancer Intergroup (GCIG). 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(Suppl):15s
54. Swisher EM, Mutch DG, Rader JS, et al. Topotecan in platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-486
55. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-3322
56. Sharma R, Graham J, Mitchell H, et al. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009;100:707-712
57. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-1849
58. Lau DH, Xue L, Young LJ, et al. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999;14:31-36
59. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105
60. Pommier Y, Kohlhagen G, Bailly C, et al. DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-13309
61. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-966
62. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-2497
63. Del Campo JM, Roszak A, Bidzinski M, et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009;20(11):1794-1802
64. Monk B, Herzog T, Kaye S, et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin in relapsed, recurrent ovarian cancer. Ann Oncol 2008;19:viii1-4
65. Rowinsky EK, Long GS, Noe DA, et al. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res 1997;3:401-407
66. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-17125
67. Smit WM, Sufliarsky J, Werner TL, et al. A phase II study evaluating the safety and efficacy of patupilone in patients with paltinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. 2009 ASCO Annual Meeting. J Clin Oncol 2009;27(Suppl):15S
68. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol 2009;27:3097-3103
69. Horowitz NS, Penson RT, Campos S, et al. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. 2008 ASCO Annual Meeting. J Clin Oncol 2008;26(Suppl):abstract 5523
70. Miller DS, Blessing JA, Krasner CN, Mannel R. A phase II evaluation of pemetrexed (LY231514, IND#40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. 2008 ASCO Annual Meeting. J Clin Oncol 2008;26(Suppl):abstract 5524
71. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-181
72. Hirte H, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. 2008 ASCO Annual Meeting. J Clin Oncol 2008;26(Suppl):abstract 5521
73. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27(33):5601-5606
74. Han LY, Landen CN, Trevino JG, et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006;66:8633-8639
75. Smith-Jones PM, Pandit-Taskar N, Cao W, et al. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 2008;35:343-351
76. Kalli KR. MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer. Curr Opin Investig Drugs 2007;8:1067-1073
77. Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007;7:6
78. Armstrong DK, Bicher A, Coleman RL, et al. Exploratory phase II efficacy study of MORAb-003, a monocolonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse. 2008 ASCO Annual Meeting. J Clin Oncol 2008;26(Suppl):abstract 5500
79. Alberts DS, Liu PY, Wilczynski SP, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007;17:784-788
80. Henriksen R, Funa K, Wilander E, et al. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993;53:4550-4554
81. Parrott JA, Kim G, Skinner MK. Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod 2000;62:1600-1609
82. Ilekis JV, Connor JP, Prins GS, et al. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997;66:250-254
83. Secord AA, Blessing JA, Armstrong DK, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:493-499
84. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005;11:5539-5548
85. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091
86. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-4332
87. Kaye SB, Poole CJ, Bidzinksi M, et al. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, paltinum sensitive ovarian cancer. 2008 ASCO Annual Meeting. J Clin Oncol 2008;26:(Suppl):abstract 5520
88. Crijns AP, Duiker EW, de Jong S, et al. Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. Int J Gynecol Cancer 2006;16(Suppl 1):152-165